Adalimumab

Mouse anti Human CD95 Antibody, Monoclonal (DX2), could be used for Flow and so on.Application:Flow: 0.5 μg/100w cellsProtein FunctionReceptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting

Mouse anti Human CD95 Antibody, Monoclonal (DX2), could be used for Flow and so on.Application:Flow: 0.5 μg/100w cellsProtein FunctionReceptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting

Kit contains 1 LF PVDF membrane, blocking buffer, wash buffer, and secondary antibody

Kit contains 1 LF PVDF membrane, blocking buffer, wash buffer, and secondary antibody

Kit contains 1 LF PVDF membrane, blocking buffer, wash buffer, and secondary antibody

Kit contains 1 LF PVDF membrane, blocking buffer, wash buffer, and secondary antibody

MISSION &#174 esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence.

MISSION &#174 esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence.

Finotonlimab (anti-PD-1) is a recombinant humanised IgG PD-1 antibody. Finotonlimab (anti-PD-1) has the potential for solid tumors or lymphomas research.

Finotonlimab (anti-PD-1) is a recombinant humanised IgG PD-1 antibody. Finotonlimab (anti-PD-1) has the potential for solid tumors or lymphomas research.

Finotonlimab (anti-PD-1) is a recombinant humanised IgG PD-1 antibody. Finotonlimab (anti-PD-1) has the potential for solid tumors or lymphomas research.

Finotonlimab (anti-PD-1) is a recombinant humanised IgG PD-1 antibody. Finotonlimab (anti-PD-1) has the potential for solid tumors or lymphomas research.